ABL kinase domain pseudoexon insertion is not uncommon in BCR-ABL transcripts

J Mol Diagn. 2008 Sep;10(5):475-6; author reply 476. doi: 10.2353/jmoldx.2008.080055. Epub 2008 Aug 7.

Abstract

This Correspondence relates to "An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy" (J Mol Diagn 2008, 10:177–180).

Publication types

  • Comment
  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Exons / genetics*
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Mutagenesis, Insertional*
  • Phosphotransferases / chemistry*
  • Phosphotransferases / genetics*
  • Piperazines / therapeutic use
  • Protein Structure, Tertiary / genetics
  • Pyrimidines / therapeutic use
  • Transcription, Genetic

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Phosphotransferases
  • Fusion Proteins, bcr-abl